Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2018

View Archived Issues

Alkahest obtains grant to develop new Parkinson's disease treatment

Pain Therapeutics resubmits Remoxy ER NDA

Novel mutation in GLA gene identified for Fabry disease

Phase I study begins of AB-569 for antibiotic-resistant bacterial lung infections

CureVac receives two new grants from the Bill & Melinda Gates Foundation

First patient treated in phase I study of NantKwest's HER2.taNK

Study predicts human doses of RVT-801 for treating Farber disease

Advaxis submits conditional MAA for axalimogene filolisbac in E.U.

Researchers develop Drosophila model of multiple sulfatase deficiency

Interim data support continuation of clinical trial testing MEI Pharma's ME-344

Durvalumab demonstrates activity in phase II CONDOR trial

In situ vaccination with a TLR ligand and anti-OX40 antibody eliminates tumors

Mallinckrodt's acquisition of Sucampo completed

Asavi identifies novel viral NS5B inhibitors

Astellas acquires Universal Cells

Moleculin Biotech and Emory University to collaborate on development of medulloblastoma treatment

Harvard College patents new vaccines for bacterial infections

FDA grants priority review to Rituxan sBLA in pemphigus vulgaris

Vaxart completes merger with Aviragen Therapeutics

Auspherix receives grant to work on organogold antibacterial compounds for respiratory infections

European Commission approves trastuzumab biosimilar Herzuma

Poseida Therapeutics patent describes MUC1-binding CARs for cancer

Merck & Co. stops APECS study of verubecestat based on DMC recommendation

Santen reports results from phase I/II study of DE-122 for AMD

Aduro BioTech Holdings Europe presents anti-PD-1 MAbs

First patient dosed in phase I/IIa study of Bicycle Therapeutics' BT-1718

IGNITE3 trial of eravacycline in cUTI trial does not meet coprimary endpoints

OBI Pharma discovers novel antibodies for cancer

Lee's licenses development and commercialization rights to GCC-4401C in China and SE Asia

Mologen enters lefitolimod agreement with Oncologie

We want your opinion - complete the TRDN user survey

Cabozantinib shows encouraging results in phase II study in differentiated thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...